Report
Nyxoah - The DREAM comes true, TP raised by 10%
Nyxoah published successful results from its US DREAM trial. All primary and secondary endpoints have been met. The company achieved an AHI responder rate of 63.5%, with 63% required for the trial to be successful. While it might seem at first sight that Inspire Medical outperformed Genio in its STAR trial with a 66% AHI responder rate, several elements from this dataset reinforce the competitive edge of Nyxoah in our view: 1/ higher median AHI reduction, 2/ efficacy in both supine/non-supine, 3/ floor effect.We are looking forward for additional data to be released to better understand the results. We believe
Underlying
Nyxoah
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Laura Roba
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.